Varian Medical Systems Inc

Varian Medical Systems — 2017 ASTRO Investor Relations Meeting

55 slides from Varian Medical Systems's conference presentation, Sep 26, 2017

  1. Slide 1: 2017 ASTRO Investor Relations Meeting: Transforming Cancer Care

    Slide 1: 2017 ASTRO Investor Relations Meeting: Transforming Cancer Care

    Varian confidential/proprietary: disclosed for immediate recipient only 2017 ASTRO Investor Relations Meeting Transforming Cancer Care

  2. Slide 2: Agenda

    Slide 2: Agenda

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Agenda 2 Treatment Delivery Technologies, HyperArc TM & Adaptive Therapy Ed Vertatschitsch Vice President, Global Portfolio Solutions Treatment Planning Systems Eric Lindquist Vice President, Clinical Solut

  3. Slide 3: Forward Looking Statements

    Slide 3: Forward Looking Statements

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 3 THIS PRESENTATION IS INTENDED EXCLUSIVELY FOR INVESTORS. IT IS NOT INTENDED FOR USE IN SALES OR MARKETING. FORWARD LOOKING STATEMENTS Except for historical information, this presentation contains forward-

  4. Slide 4: Overview

    Slide 4: Overview

    Varian confidential/proprietary: disclosed for immediate recipient only Varian Overview Dow R. Wilson President and Chief Executive Officer

  5. Slide 5: Varian today – a snapshot

    Slide 5: Varian today – a snapshot

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Varian today – a snapshot 5 * Varian FY 16, excluding Imaging Components. ** YTD thru Fiscal 3 rd quarter 2017 Gross Orders, excluding North America A focused cancer company Global Leader in radiation thera

  6. Slide 6: Long-term growth and value creation strategy

    Slide 6: Long-term growth and value creation strategy

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Medical oncology Precision medicine Diagnostic imaging Radiation oncology Interventional oncology Surgical oncology Long - term growth and value creation strategy 6 Global Leader in Radiation Therapy #1 Glo

  7. Slide 7: Growth priorities and strategic enablers

    Slide 7: Growth priorities and strategic enablers

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Growth priorities and strategic enablers 7 We are here Global Leader in Radiation Therapy Integrated, Human - Centered Cancer Treatment Strengthen Leadership in Radiation Therapy Extend Global Footprint Exp

  8. Slide 8: In summary

    Slide 8: In summary

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 8 In summary • Global market leader today with the strongest portfolio • Strengthening our leadership in radiation therapy • Growth - focused in both developed and developing markets • Financially disciplin

  9. Slide 9: Proton Therapy

    Slide 9: Proton Therapy

    Varian confidential/proprietary: disclosed for immediate recipient only Proton Therapy Moataz Karmalawy VP & General Manager Worldwide Particle Therapy

  10. Slide 10: Proton therapy plays a critical role in strengthening our leadership

    Slide 10: Proton therapy plays a critical role in strengthening our leadership

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Proton therapy plays a critical role in strengthening our leadership Key luminaries adding proton therapy Protons expand to new disease sites Innovation leader IMPT and compact systems Melanoma of the eye B

  11. Slide 11: True integration

    Slide 11: True integration

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY True integration 11 Simplification, automation, human - centered design ARIA ® Oncology Information System 360 Oncology ™ Care Management Platform Velocity ™ Oncology Image Informatics Eclipse ™ Treatment P

  12. Slide 12: ProBeam installations

    Slide 12: ProBeam installations

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY PAUL SCHERRER INSTITUTE (PSI) 1 Rotational Gantry MARYLAND PROTON TREATMENT CENTER 4 Rotational Gantries and 1 Fixed Beam Room HEFEI ION MEDICAL CENTER 3 Rotational Gantries, 1 Fixed Beam, and 1 Research Ro

  13. Slide 13: Extending global footprint: ProBeam approvals

    Slide 13: Extending global footprint: ProBeam approvals

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Extending global footprint: ProBeam ® approvals ProBeam ® now has clearance in the US, Europe and Japan FDA Clearance in US CE Mark in Europe Shonin Clearance in Japan 11

  14. Slide 14: Large growth opportunity in China

    Slide 14: Large growth opportunity in China

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 14 Large growth opportunity in China • 2 proton centers in operation • 10 proton centers in progress • 15 - 20 proton purchase contracts in next 10 years • Varian with first government - funded project in H

  15. Slide 15: ProBeam: Integrated, human-centered cancer treatment

    Slide 15: ProBeam: Integrated, human-centered cancer treatment

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 15 ProBeam I ntegrated , human - centered cancer treatment

  16. Slide 16: Oncology Systems

    Slide 16: Oncology Systems

    Varian confidential/proprietary: disclosed for immediate recipient only Oncology Systems Kolleen T. Kennedy President, Oncology Systems Treatment Delivery Technologies Adaptive Therapy Ed Vertatschitsch Vice President, Global Portfolio Solutions Treatment Planning Systems Eric Lindquist Vice Preside

  17. Slide 17: Oncology Systems

    Slide 17: Oncology Systems

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Oncology Systems 17

  18. Slide 18: ASTRO highlights

    Slide 18: ASTRO highlights

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY ASTRO highlights 18 Varian Presence • First Halcyon patient treated at Penn Medicine; UCSD also treating • First HyperArc TM treatment in Negrar , Italy • Strong attendance and participation ; 1,054 custome

  19. Slide 19: Varian market leadership

    Slide 19: Varian market leadership

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Varian market leadership 19 Leading provider of integrated, human - centered cancer treatment solutions Halcyon growth enabler in single L inac centers, small vaults IMV t op scores in all key categories Po

  20. Slide 20: The Varian ecosystem promise delivered

    Slide 20: The Varian ecosystem promise delivered

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY The Varian ecosystem promise delivered 20 Intelligent Treatment Delivery • Halcyon platform launch • HyperArc SRS • iCBCT soft tissue visualization Knowledge - Based Oncology • Eclipse • RapidPlan • Multi -

  21. Slide 21: Oncology growth drivers

    Slide 21: Oncology growth drivers

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Oncology growth drivers • Global Demographics • Winning Innovation Strategy • Emerging Markets Opportunity • Services Business Expansion • Software Momentum • Aging Installed Base 21 Long - term goal 6M pat

  22. Slide 22: Treatment Delivery Systems

    Slide 22: Treatment Delivery Systems

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Treatment Delivery Systems 22

  23. Slide 23: Halcyon for value-based healthcare

    Slide 23: Halcyon for value-based healthcare

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Halcyon for value - based healthcare 23 Accelerate installation and clinical go - live Reduce footprint and cost of ownership Treat more patients per day with ease High - quality image - guided IMRT treatme

  24. Slide 24: Accessing markets worldwide: regulatory progress

    Slide 24: Accessing markets worldwide: regulatory progress

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Accessing markets worldwide: regulatory progress 24 Cleared In - process No clearance required • Parallel filings in major markets • Clearance in 113 countries • Filings under government review: China, Japa

  25. Slide 25: First-in-country orders

    Slide 25: First-in-country orders

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY First - in - country orders • Australia • Belgium • India • Morocco 25 • Romania • Russia • Turkey • UK

  26. Slide 26: Operational readiness at a global scale

    Slide 26: Operational readiness at a global scale

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Operational readiness at a global scale 26 Manufacturing Sites Education Centers Parts Depots FOR INVESTOR USE ONLY

  27. Slide 27: Halcyon strengthens radiotherapy leadership

    Slide 27: Halcyon strengthens radiotherapy leadership

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Strengthens radiotherapy leadership • Leverage core linac competency • Enable key intellectual property • Develop critical supply chain 27 • Delivers outstanding clinical quality • Enhances patient comfort

  28. Slide 28: Halcyon summary

    Slide 28: Halcyon summary

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 28 FOR INVESTOR USE ONLY Extends global access to world - class radiotherapy Delivers total value of ownership for hospitals Establishes a next - gen platform for future innovation Halcyon summary

  29. Slide 29: Adaptive Therapy

    Slide 29: Adaptive Therapy

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Adaptive Therapy 29

  30. Slide 30: Patients and tumors change over time

    Slide 30: Patients and tumors change over time

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 30 Patients and tumors change over time • Tumors shrink and change shape as they respond to therapy • Patient physiology may change due to weight loss and medication • Treatment plans should adapt Adaptive

  31. Slide 31: Future of RT requires combined modalities

    Slide 31: Future of RT requires combined modalities

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Future of RT requires combined modalities 31 Only Varian Multi - modality imaging at point of care Single - modality image - guidance Other approaches Lower left image courtesy of Siemens Healthineers . CT

  32. Slide 32: Therapeutic accuracy is vital

    Slide 32: Therapeutic accuracy is vital

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Therapeutic accuracy is vital Fast and accurate adaptive workflow is critical for the patient comfort, stability, and clinic efficiency Treatment Fidelity High - definition treatment enables delivered dose

  33. Slide 33: Adaptive therapy strategy

    Slide 33: Adaptive therapy strategy

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 33 Adaptive therapy strategy Strengthening Varian’s leadership in radiation oncology through: • Multimodality imaging ; Available for every patient ; Most informed adaptive decisions • Iterative CBCT for ac

  34. Slide 34: HyperArc

    Slide 34: HyperArc

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY HyperArc TM 34

  35. Slide 35: Global need for SRS solutions

    Slide 35: Global need for SRS solutions

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Global need for SRS solutions 32 1 DeSantis CE, Cancer treatment and survivorship statistics, 2014 CA. Metastatic brain cancer ~15M patients over 5 years of cancer patients will develop brain metastases 1 4

  36. Slide 36: HyperArc high-definition radiotherapy

    Slide 36: HyperArc high-definition radiotherapy

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY HyperArc ™ high - definition radiotherapy 36 Establishing new benchmarks for radiosurgery Treatment quality • Algorithms unlock TrueBeam /Edge system capabilities • Maximize healthy tissue sparing Unmatched

  37. Slide 37: HyperArc high-definition radiotherapy: $300M opportunity

    Slide 37: HyperArc high-definition radiotherapy: $300M opportunity

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 37 HyperArc ™ high - definition radiotherapy • TrueBeam and Eclipse upgrade opportunity • High product and service margins • Potential to accelerate older system replacements Benchmark radiosurgery scalable

  38. Slide 38: Treatment Planning Systems

    Slide 38: Treatment Planning Systems

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Treatment Planning Systems 38

  39. Slide 39: Treatment planning

    Slide 39: Treatment planning

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Treatment planning • For the fourth year in a row, Eclipse named category leader by KLAS • Over 3,900 Eclipse customers worldwide • 900+ RapidPlan licenses growing double digits 36

  40. Slide 40: Treatment planning workflow

    Slide 40: Treatment planning workflow

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Treatment planning workflow 40 Contouring Plan Optimization Dose Calculation Eclipse TM Benefits • Accuracy • Efficiency • Flexibility • Automation • Interactivity • Speed

  41. Slide 41: RapidPlan: Transforming efficiency

    Slide 41: RapidPlan: Transforming efficiency

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Contouring Plan Optimization Dose Calculation Trade - Off Analysis RapidPlan 41 Transforming efficiency Knowledge Guidance RapidPlan

  42. Slide 42: RapidPlan benefits

    Slide 42: RapidPlan benefits

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Benefits Quality Increased Consistency Efficiency RapidPlan 42 Transforming efficiency

  43. Slide 43: Multi-Criteria Optimization

    Slide 43: Multi-Criteria Optimization

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Multi - Criteria Optimization 43 Transforming efficiency Contouring Plan Optimization Dose Calculation Trade - Off Analysis Plan Fine Tuning Multi - Criteria Optimization

  44. Slide 44: RapidPlan + Multi-Criteria Optimization

    Slide 44: RapidPlan + Multi-Criteria Optimization

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY RapidPlan + Multi - Critera Optimization 44 Efficient and patient centric RapidPlan MCO

  45. Slide 45: Multi-Criteria Optimization benefits

    Slide 45: Multi-Criteria Optimization benefits

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Multi - Criteria Optimization For Varian • Strengthens leadership position • Drives incremental RapidPlan adoption • Extends global footprint 45 For Clinicians • Allows for fine - tuning and customizing eac

  46. Slide 46: Driving customer productivity

    Slide 46: Driving customer productivity

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Driving customer productivity 46 Increased GPU speed* Contouring Plan Optimization Dose Calculation Trade - Off Analysis GPU Speed GPU Speed GPU CPU 25x improvement 5x improvement 5x improvement Lung Total

  47. Slide 47: Eclipse treatment planning

    Slide 47: Eclipse treatment planning

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 47 Eclipse treatment planning • Solid core user base of over 3,900 customers worldwide • High - value upgrades to customers • HyperArc and RapidPlan are unique value creators • MCO and GPU elevate planning

  48. Slide 48: Oncology Continuum Solutions

    Slide 48: Oncology Continuum Solutions

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Oncology Continuum Solutions 48

  49. Slide 49: ARIA: market-leading oncology information system

    Slide 49: ARIA: market-leading oncology information system

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY ARIA: market - leading oncology information system • Extending global footprint with localization • Strengthening leadership with cybersecurity • Timely compliance with US regulations • Rapid expansion of i

  50. Slide 50: InSightive: real-time insights, better informed decisions

    Slide 50: InSightive: real-time insights, better informed decisions

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY • An intuitive analytics solution built specifically for the oncology department • Simple, interactive exploration of oncology data to uncover patterns and trends • Helps improve care, operational performan

  51. Slide 51: Velocity software

    Slide 51: Velocity software

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY • Organizes unstructured and disparate patient image data into rich patient history • Uses images to provide clinical insights for tumor response and treatment planning • Vendor - neutral platform for the m

  52. Slide 52: Streamlining Multi-Disciplinary Tumor Boards

    Slide 52: Streamlining Multi-Disciplinary Tumor Boards

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 52 360 Oncology Enabling simpler, smarter cancer care Streamlining Multi - Disciplinary Tumor Boards 1 1 Financial analysis based on British Journal of Cancer (2013) 109, 2295 – 2300 | doi : 10.1038/bjc.201

  53. Slide 53: Building the operating system for cancer care

    Slide 53: Building the operating system for cancer care

    Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 53 360 Oncology Building the operating system for cancer care • Early entry into the $1B+ market for oncology care coordination and clinical decision support • Focus on serving critical unmet needs in oncol

  54. Slide 54: Closing Remarks

    Slide 54: Closing Remarks

    Varian confidential/proprietary: disclosed for immediate recipient only Closing Remarks Dow R. Wilson President and Chief Executive Officer

  55. Slide 55: FOR INVESTOR USE ONLY

    Slide 55: FOR INVESTOR USE ONLY

    FOR INVESTOR USE ONLY 55

Source: SEC EDGAR · 8-K filed Sep 26, 2017

More decks from Varian Medical Systems Inc